Keixing Announces the Completion of the First Patient Enrollment in the Chinese Cohort of the Phase 3 aficamten Clinical Trial

Keixing Pharma (“Jixing”), a biopharmaceutical company dedicated to providing innovative medicines for patients suffering from serious life-threatening health conditions, announced its aficamten (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Developed by Cytokinetics, Aficamten is a potential next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM)

"Hypertrophic cardiomyopathy is a common hereditary cardiovascular disease, and the existing drug therapy is recommended on the basis of empirical treatment, not targeting the underlying pathological mechanism of HCM, namely excessive myocardial contraction

"At present, there is no approved therapeutic drug targeting the underlying pathophysiological mechanism of oHCM in China.

SEQUOIA-HCM is based on positive results from Cytokinetics' Phase 2 aficamten clinical trial, REDWOOD-HCM, which showed that mean resting left ventricular outflow tract gradient (LVOT-G) after 10 weeks of aficamten treatment compared with placebo Mean LVOT-G was reduced from baseline after both and valsalva maneuvers, and there were no treatment interruptions or discontinuations, and no treatment-related serious adverse events

About Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiovascular disease, with a prevalence of 80/100,000 in China, and it is estimated that there are more than 1 million adult HCM patients in China

At present, there are no approved drugs for HCM directly in China.